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with 44 mcg scIFNβ 1a in patients with EDSS > 3.5–5.0 was 1.21 per patient over 2 
years. The mean number of relapses avoided for the overall study population was 
0.74 per patient over 2 years. The average cost-effectiveness of 44 mcg scIFNβ 1a 
was estimated to be $107,861 per relapse avoided for the EDSS > 3.5–5.0 cohort. The 
average cost-effectiveness for the overall study population was estimated to be 
$181,208 per relapse avoided. Sensitivity analyses showed that results were robust 
to changes in key input parameters such as DMD costs, the number of relapses in 
untreated patients, the relative risk reduction in clinical relapse rates, the rate of 
adherence, and the average cost of relapse. ConClusions: Based on model results, 
the average cost-effectiveness of 44 mcg scIFNβ 1a was favorable for both the overall 
study population and the EDSS > 3.5–5.0 cohort.
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objeCtives: To estimate the cost-utility of sacral anterior root stimulation (SARS, 
using the Finetech-Brindley device) compared to medical treatment (anticholiner-
gics + catheterization) in complete spinal cord injured patients with a neurological 
bladder. Methods: A probabilistic Markov model was elaborated with a 10-year 
time-horizon, one-year cycles and a 2.5% discount rate. Three irreversible states 
were defined: 1) treatment without urinary complication; 2) surgery for urinary com-
plication (sphincterotomy, urinary derivation); 3) death. Reversible states (urinary 
calculi; Finetech-Brindley device failures) were integrated in the two first irreversible 
states. A systematic review and meta-analysis were performed to estimate transi-
tion probabilities and Quality Ajusted Life Years (QALYs). In the perspective of the 
French Healthcare System, costs were estimated from a published comparative 
cost-effectiveness research (Neurosurgery 2014; 73: 600), and through simulations 
using the 2013 French prospective payment system (PMSI) classification. Results: 
In the primary analysis, the cost-utility ratio was 10,647€ /QALY gained. At a 30,000€ 
ceiling ratio the probability of SARS being cost-effective compared to medical treat-
ment was 63%. If the French Healthcare System reimbursed SARS for 200 patients/
year the two first years and 50 patients/year during 8 years (anticipated target 
population) the expected incremental net health benefit would be 222 QALYs, and 
the expected value of perfect information (EVPI) would be 4,570,000€ . The highest 
partial EVPI is reached for transition probabilities toward urinary calculi (4,420,000€ ). 
With discount rates of 1% and 6% the cost-utility ratios were 6,951 and 19,770€ /
QALY gained, and the probabilities of SARS being cost-effective were 66% and 58%, 
respectively. ConClusions: Our model shows that SARS using Finetech-Brindley 
device offers the most important benefit and should be considered cost-effective 
at a 30,000€ ceiling ratio. Despite a high uncertainty, EVPI and partial EVPI may 
indicate that further research would not be profitable to inform decision making.
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objeCtives: Multiple sclerosis (MS) is a disease with lifelong impact, making the 
cost-effectiveness (CE) of its treatments particularly sensitive to assumptions 
embedded in model designs. Traditional sensitivity analysis (SA) can test many 
assumptions, but it is not designed to investigate sensitivity to structural assump-
tions. The aim of this study was to compare a Markov cohort model (MM) and a 
discrete-event simulation (DES) model of MS that were based on common clinical 
data but developed independently to understand the impact of their structural dif-
ferences on model predictions. Methods: A similar population was simulated in 
the MM and the DES model; aggregated cost and utility estimates were compared 
over varying time horizons. The average expanded disability status scale (EDSS) and 
the distribution of EDSS were also compared over time to study the dynamics of 
disease progression and treatment effects. Results: The two modeling approaches 
led to different natural history behavior over longer time horizons, even after short-
term behaviors were well-aligned, with the DES model predicting slightly fewer 
life-years (25.9 vs. 26.2 in the MM) but more quality-adjusted life-years (9.6 vs. 8.1 
in the MM). These differences reflect slower progression of EDSS in the DES model, 
particularly to higher EDSS states. When disease history (including a baseline EDSS 
term) was excluded from the DES model, the natural history simulations of the 
two models agreed more closely. ConClusions: Structural SA can help quantify 
the impact of key modeling decisions. In this study, a comparison of an MM and 
a DES model showed that natural history predictions diverge over long time hori-
zons, in part due to the consideration of disease history in the DES model. A better 
understanding of the differences between the two model designs helps ensure 
interpretation of the model results while taking into consideration the assumptions 
embedded in those designs.
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objeCtives: To evaluate the cost-effectiveness of glatiramer acetate (Copaxone®) 
as a disease-modifying treatment (DMT) for relapsing-remitting multiple scle-
rosis (RRMS) compared to intravenous [natalizumab (Tysabri®), alemtuzumab 
(Lemtrada®) ] or subcutaneous injectables [interferon-beta-1b (Betaferon®), inter-
feron-beta-1a 44mcg, 22mcg, 30mcg (Rebif-44®, Rebif-22®, Avonex®) ] and oral DMTs 
[fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®), teriflunomide (Aubagio®)].  
Methods: A Markov model followed patients over 50 years through 21 health 
and secondary analysis, respectively. Extensive sensitivity analyses indicated that 
results were robust. The most influential parameters were the utility estimates, 
probability of hospitalization per seizure and unit cost of hospitalization. The BIA 
showed that the annual cost of treating uncontrolled epileptic patients with LCM 
in Greece ranges between € 274.9 and € 271.5 million, in the primary and secondary 
analyses, respectively, compared to the respective costs with standard AED (€ 277.3 
and € 279.9 million). ConClusions: LCM appears to be both less costly and more 
effective compared with standard AED treatment in Greece and results in cost sav-
ings ranging between € 2.4 and € 8.3 million. Study funded by UCB Pharma.
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objeCtives: To estimate the cost-effectiveness of Interferon beta-1a subcutane-
ous (SC) when compared with Interferon beta-1a intramuscular (IM) in Portugal, 
based on the findings published by the Cochrane review of first-line treatments for 
relapse-remitting multiple sclerosis. Methods: An Excel-based model estimated 
the number of relapses and costs incurred by a cohort of 3,000 patients treated 
with two types of interferon beta-1a. The model evaluated the consequences of 
each treatment based on the findings of a Cochrane meta-analysis (Filippini 2013). 
The analysis was performed from a Portuguese NHS perspective, including only 
direct costs. Costs of relapse were obtained from a local publication (Mateus C, 
2000) whereas costs of both drugs were obtained from local official databases (Cat@
logo). Although efficacy was kept constant as Cochrane did not report outcomes 
based on EDSS, costs of relapse were available for patients with different EDSS 
values, thus allowing estimation of cost-effectiveness for different types of popu-
lation. Results: According to the model, over a 2 year period and in a population 
with EDSS ≤ 3, treatment with IM interferon beta-1a will result in a total of 2,228 
relapses, and a total cost of 69,572,717€ , whereas treatment with SC interferon beta-
1a will result in 1,709 relapses and a total cost of 70,480,835€ . For a population with 
EDSS between 3.5 and 4.5 cost values for IM and SC are 72,141,975€ and 72,451,135€ , 
respectively. Cost-effectiveness ratios were 1,748€ per relapse avoided when EDSS ≤ 
3 and 595€ per relapse avoided when EDSS was between 3.5 and 4.5. ConClusions: 
Considering that the cost of a relapse varies between 3,896€ (EDSS ≤ 3) and 5,139€ 
(EDSS between 3.5 and 4.5) the incremental cost-effectiveness ratios found for 
interferon beta-1a SC seem to indicate that that SC interferon beta-1a is a cost-
effective alternative to the use of IM interferon beta-1a.
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objeCtives: To investigate the cost-effectiveness of treating vs. not treating 
obstructive sleep apnea (OSA) in Italy and France Methods: A 5-year, 10-state 
Markov model with disease states including; disease and event-free with OSA, dia-
betes, hypertension, myocardial infarction [MI], post-MI, stroke, post-stroke, atrial 
fibrillation [AF], heart failure [HF], and death; was developed to compare costs, out-
comes, and event-free life-years (LYS) of treating vs not treating OSA from the Italian 
National Health Service (INHS) and French National Health System (FNSH) view-
point. Health care resources included those related to diagnosis, treatment (CPAP 
only) and follow-up of OSA; management of hypertension, diabetes, HT, AF, post MI, 
and post-stroke (per year); MI, and stroke (per episode). Health care resources were 
valued at Euro (€ ) 2012 using published sources. Results: After 5 years the number 
of incremental event-free LYS per patient treated for OSA reaches 0.31 (Italy: 4.15 
vs 3.84; France: 4.07 vs 3.76). Treating OSA incurs an incremental cost of € 1011.01 
and € 2998.45per patient for Italy and France, respectively. The ICER of treating OSA 
is € 3212.39 for Italy and € 9777.09 for France, respectively. ConClusions: Treating 
OSA can be considered highly cost-effective for both the INHS and the FNSH when 
compared to the acceptability range for incremental cost effectiveness proposed 
for Italy (€ 25,000-€ 40,000) and for Europe (€ 50,000).
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objeCtives: To evaluate the cost-effectiveness of 44 mcg subcutaneous interferon 
beta-1a (scIFNβ 1a) in patients with multiple sclerosis (MS) with Kurtzke Expanded 
Disability Status Scale (EDSS) score > 3.5–5.0. Methods: The analysis was per-
formed from a US payer perspective. The time horizon of the analysis was 2 years. 
The decision analytic model was populated with real-world inputs and related 
assumptions, as well as pivotal placebo-controlled clinical trial data for 44 mcg 
scIFNβ 1a 3 times a week (PRISMS Study). Clinical inputs were obtained for the overall 
study population as well as a subpopulation of patients with Kurtzke EDSS score 
> 3.5–5.0. Disease-modifying drug (DMD) cost was based on 2014 wholesale average 
cost with consideration of patient copayment in the base case. Sensitivity analyses 
were conducted on key input variables to assess their impact on cost per relapse 
avoided. Results: Model results showed that the mean number of relapses avoided 
